TICKERNERD
Menu
CLOVCLOVHealthcare · Healthcare Plans

CLOV Stock Forecast: Clover Health Investments Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.15
+1.22% on the day

The 3 Wall Street analysts covering Clover Health Investments Corp. hold a median 12-month price target of $5 — +20.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.2B
Ticker Nerd rank
66 / 100
Median analyst target
$5.00
Analysts covering
3
Total return, dividends reinvested
1W
−9.8%
1M
−13.4%
YTD
+76.6%
1Y
+59.0%
From 52W high
−23.3%
From 52W low
+144.1%
$1.70
$5.41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clover Health Investments Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Growth
68
Momentum
65
Accruals
63
Issuance
56
Value
45
Quality
45
Size
36
Volatility
20

Revisions (89): Analysts have, on balance, been raising their forecasts.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26CLOVHigh $5.50Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $5.00Median $5.00High $5.50

The green dot is the last close — the median target sits +20.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026UBSMaintainsNeutral$4.75 → $5.00
21 July 2026Canaccord GenuityMaintainsBuy$4.20 → $5.50
21 July 2026Canaccord GenuityMaintainsBuy—
11 June 2026UBSMaintainsNeutral$2.75 → $4.75
11 June 2026UBSMaintainsNeutral—
4 June 2026Canaccord GenuityMaintainsBuy$3.20 → $4.20
4 June 2026Canaccord GenuityMaintainsBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026Leerink PartnersMaintainsMarket Perform—
20 Jan 2026Canaccord GenuityMaintainsBuy—
6 Nov 2025Canaccord GenuityMaintainsBuy—
7 Aug 2025Canaccord GenuityMaintainsBuy—
6 Aug 2025UBSMaintainsNeutral—
3 Mar 2025Canaccord GenuityMaintainsBuy—
17 Dec 2024Craig-HallumInitiatesBuy—
7 Oct 2024UBSInitiatesNeutral—
11 Aug 2023CitigroupMaintainsNeutral—
6 Mar 2023Canaccord GenuityMaintainsBuy—
6 Mar 2023Credit SuisseMaintainsUnderperform—
16 Nov 2022CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLOV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+75.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

Clover Health Investments Corp. (CLOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−24.5×

Cheaper than 96% of US stocks

Price / sales
0.9×

Cheaper than 72% of US stocks

Price / book
5.8×

Cheaper than 19% of US stocks

EV / EBITDA
−109.2×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
55.6%

Higher than 88% of US stocks

Earnings growth (YoY)
55.6%

Higher than 76% of US stocks

Gross margin
20.6%

Higher than 22% of US stocks

Operating margin
3.8%

Higher than 52% of US stocks

Net margin
−0.7%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−5.1%

Higher than 39% of US stocks

Return on assets
−1.8%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CLOVClover Health Investments Corp.$2.2B
66
PGNYProgyny, Inc.$2.0B
97
ALHCAlignment Healthcare, Inc.$2.7B
69
OSCROscar Health, Inc.$9.5B
84
MOHMolina Healthcare, Inc.$10.3B
32
CNCCentene Corp.$32.0B
93
TRLVTrulieve Cannabis Corp.*$2.1B
88

* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clover Health Investments Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLOV news & analysis

Clover Health Investments: Real Turnaround, But Already Priced In

Seeking Alpha · 15 Aug 2026neutral

Seeking Alpha rates Clover Health Investments (CLOV) a Hold, citing improved operational execution — Medicare Advantage membership grew 48% year over year and revenue and GAAP net income improved — but with a cautious outlook due to valuation and litigation risks. The firm notes profitability per member lags FY2024 levels, FY2026 guidance implies negative second-half results, and $120 million in quality bonus revenue is at risk pending a CMS litigation outcome.

Why it matters — For CLOV watchers, this item highlights that while the company's operational turnaround is real, the stock may already reflect that progress, leaving valuation and a potential CMS litigation outcome as key risks to the outlook.

Clover Health Is Proving Its Profit Model

Seeking Alpha · 14 Aug 2026positive

Clover Health reported strong growth and profitability, with improved guidance. Medicare Advantage membership grew 48% year-over-year, revenue rose 56%, and gross profit increased 54%, driven by cohort maturation and the Clover Assistant platform.

Why it matters — A CLOV watcher would care because Clover Health continues to post double-digit growth across membership, revenue, and gross profit while raising its guidance, signaling the durability of its profit model.

Clover Health Eyes 2026 GAAP Profit as AI Platform Fuels Medicare Advantage Growth

MarketBeat · 11 Aug 2026positive

Clover Health's interim CFO Clay Thornton outlined the company's Medicare Advantage strategy centered on earlier chronic condition detection and treatment, supported by its AI platform, during a Canaccord Genuity conference presentation.

Why it matters — CLOV watchers would care because the company's path to GAAP profitability in 2026 hinges on the success of its AI-driven approach to Medicare Advantage growth.

Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Clover Health Investments Corp.'s Q2 2026 earnings call, titled "Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript."

Why it matters — A CLOV watcher would use the transcript to review the company's own commentary on its quarterly results and outlook.

Clover Health Investments Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Clover Health Investments reported second-quarter results showing continued Medicare Advantage membership growth alongside profitability, and raised its full-year 2026 outlook across its key financial measures.

Why it matters — A CLOV watcher would care because continued membership growth, profitability, and a raised full-year outlook point to strengthening performance across the company's core financial measures.

FAQ

Frequently asked questions about CLOV stock

What is the CLOV stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Clover Health Investments Corp. have a median 12-month price target of $5, with estimates ranging from $5 to $5.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLOV stock a buy right now?

Of the 3 analysts covering Clover Health Investments Corp., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clover Health Investments Corp. 66 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLOV?

As at 22 Aug 2026, Clover Health Investments Corp. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will CLOV stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +20.5% from the last close, and Ticker Nerd's factor model ranks Clover Health Investments Corp. 66 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLOV stock forecast for 2030?

No analyst covering Clover Health Investments Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5.5 over the next 12 months.

How has CLOV stock performed over the past year?

Clover Health Investments Corp. returned +59.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clover Health Investments Corp. do?

Clover Health Investments, Corp. is a healthcare technology and insurance company focused on the U.S.

What is the latest news on CLOV?

The most recent item we track (Seeking Alpha, 15 Aug 2026): "Clover Health Investments: Real Turnaround, But Already Priced In". Seeking Alpha rates Clover Health Investments (CLOV) a Hold, citing improved operational execution — Medicare Advantage membership grew 48% year over year and revenue and GAAP net income improved — but with a cautious outlook due to valuation and litigation risks. The firm notes profitability per member lags FY2024 levels, FY2026 guidance implies negative second-half results, and $120 million in quality bonus revenue is at risk pending a CMS litigation outcome.

Company

About Clover Health Investments Corp.

Clover Health Investments, Corp. is a healthcare technology and insurance company focused on the U.S. Medicare Advantage market. The company offers preferred provider organization (PPO) and health maintenance organization (HMO) plans to Medicare-eligible beneficiaries across several states, operating primarily through its Insurance segment. Clover Health Investments, Corp. differentiates itself by integrating its proprietary cloud-based software platform, Clover Assistant, into clinical workflows. This platform aggregates and analyzes patient data to provide physicians with personalized, real-time insights at the point of care, supporting earlier detection and more proactive management of chronic diseases. By combining technology-driven decision support with Medicare Advantage plan design, Clover Health Investments, Corp. aims to enhance care coordination, reduce avoidable medical costs, and improve health outcomes for seniors. The company serves a network of physicians and medical groups while targeting an aging population that increasingly relies on managed care solutions. Founded in 2014 and headquartered in Franklin, Tennessee, Clover Health Investments, Corp. occupies a niche at the intersection of healthcare plans and digital health enablement.

CEO Mr. Andrew Toy · 570 employees · United States · https://www.cloverhealth.com